InspireMD, Inc. Announces Pricing of Public Offering of Common Stock
27 févr. 2018 07h00 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL , Feb. 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
InspireMD Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard EPS in South Korea
22 févr. 2018 10h16 HE
|
InspireMD, Inc.
Solvit Medical to fund all regulatory, registration and reimbursement submissions TEL AVIV, ISRAEL, Feb. 22, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in...
InspireMD Announces Commercial Launch and First Sales of CGuard™ EPS in India
20 févr. 2018 09h00 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Feb. 20, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Announces Fourth Quarter and Year-End 2017 Results; CGuard™ EPS Fourth Quarter Sales Increase 211% Versus Same Period Last year
14 févr. 2018 07h30 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Feb. 14, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD's CGuard Embolic Prevention System Featured in a Second Live Case Transmission at LINC 2018 by Leading Interventional Cardiologists
31 janv. 2018 08h31 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 31, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD’s CGuard Embolic Prevention System to be Prominently Featured in Two Live Case Transmissions at LINC 2018
26 janv. 2018 10h11 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 26, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Announces Publication of an Independent Imaging Study Highlighting the Advantages of CGuard EPS Compared to Another Next Generation Carotid Stent
19 janv. 2018 10h18 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 19, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD’s CGuard EPS Demonstrates Improved Outcomes over Carotid Endarterectomy in 50 Patient Comparative Study; Preliminary Results Featured at the 7th Munich Vascular Conference 2017
07 déc. 2017 12h23 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Dec. 07, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
InspireMD Announces Preliminary 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard™ EPS
05 déc. 2017 13h00 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Announces Expansion of its Distribution Network for CGuard™ EPS in Australia, New Zealand and Vietnam
04 déc. 2017 09h45 HE
|
InspireMD, Inc.
TEL AVIV, lSRAEL, Dec. 04, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...